Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cevostamab in Chinese Patients With Relapsed or Refractory Multiple Myeloma
NCT06934044Phase 1Active, not recruiting
- Sponsor
- Roche
- Start
- May 2025
- Primary completion
- Nov 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cevostamab in multiple myeloma (MM), sponsored by Roche. Primary endpoints: Serum Concentration of Cevostamab and Percentage of Participants with Adverse Events. Started May 2025; status: active, not recruiting.
02
Drugs
cevostamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06934044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06934044.